Samsung Biologics’ unionized workers stage another partial strike on Friday, continuing a labor dispute that has lasted more than six months. The strike, involving about 400 workers (roughly 10% of the company’s union membership), is set to run for around three weeks through Nov. 27. Workers in areas including quality control testing, quality assurance, logistics and production participate in the stoppage.

The dispute centers on 2026 wage and collective bargaining negotiations between labor and management. Samsung Biologics and the labor side declared negotiations broken down in March, after which the union carried out a partial strike in April—the first since the company began operations in 2011. Samsung Biologics’ global competitors are also expanding contract drug manufacturing capacity, raising concerns that the extended strike could affect the company’s ability to deliver promised drug volumes on time. Across outlets, the reported focus is on the strike schedule, the share of participants, and the ongoing bargaining breakdown.

Some outlets emphasize the reliability and supply-risk angle stemming from slower production, while others foreground the action itself—another partial stoppage by union members and its stated duration.